Multiple Computational Approaches for Predicting Drug Interactions with Human Equilibrative Nucleoside Transporter 1.

Drug Metab Dispos

College of Pharmacy, Department of Pharmacology & Toxicology (S.R.M., N.J.C.), and College of Medicine, Department of Physiology (S.H.W.), University of Arizona, Tucson, Arizona; and Collaborations Pharmaceuticals, Inc., Raleigh, North Carolina (T.R.L., K.M.Z., S.E.)

Published: July 2021

AI Article Synopsis

  • Equilibrative nucleoside transporters (ENTs) are important in how nucleoside analog drugs are absorbed and distributed in the body, with implications for treating diseases like cancer and viral infections.
  • The study created 3D models to better understand how different drugs interact with ENT1 and ENT2, revealing unique characteristics for substrates and inhibitors.
  • NBMPR, an ENT-specific inhibitor, significantly reduced the accumulation of drugs like mizoribine and ribavirin in cells, while darunavir showed limited interaction, helping to inform future drug development and selection processes.

Article Abstract

Equilibrativenucleoside transporters (ENTs) participate in the pharmacokinetics and disposition of nucleoside analog drugs. Understanding drug interactions with the ENTs may inform and facilitate the development of new drugs, including chemotherapeutics and antivirals that require access to sanctuary sites such as the male genital tract. This study created three-dimensional pharmacophores for ENT1 and ENT2 substrates and inhibitors using K and IC data curated from the literature. Substrate pharmacophores for ENT1 and ENT2 are distinct, with partial overlap of hydrogen bond donors, whereas the inhibitor pharmacophores predominantly feature hydrogen bond acceptors. Mizoribine and ribavirin mapped to the ENT1 substrate pharmacophore and proved to be substrates of the ENTs. The presence of the ENT-specific inhibitor 6--[(4-nitrophenyl)methyl]-6-thioinosine (NBMPR) decreased mizoribine accumulation in ENT1 and ENT2 cells (ENT1, ∼70% decrease, = 0.0046; ENT2, ∼50% decrease, = 0.0012). NBMPR also decreased ribavirin accumulation in ENT1 and ENT2 cells (ENT1: ∼50% decrease, = 0.0498; ENT2: ∼30% decrease, = 0.0125). Darunavir mapped to the ENT1 inhibitor pharmacophore and NBMPR did not significantly influence darunavir accumulation in either ENT1 or ENT2 cells (ENT1: = 0.28; ENT2: = 0.53), indicating that darunavir's interaction with the ENTs is limited to inhibition. These computational and in vitro models can inform compound selection in the drug discovery and development process, thereby reducing time and expense of identification and optimization of ENT-interacting compounds. SIGNIFICANCE STATEMENT: This study developed computational models of human equilibrative nucleoside transporters (ENTs) to predict drug interactions and validated these models with two compounds in vitro. Identification and prediction of ENT1 and ENT2 substrates allows for the determination of drugs that can penetrate tissues expressing these transporters.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8313052PMC
http://dx.doi.org/10.1124/dmd.121.000423DOI Listing

Publication Analysis

Top Keywords

ent1 ent2
24
drug interactions
12
accumulation ent1
12
ent2 cells
12
cells ent1
12
ent1
11
ent2
9
human equilibrative
8
equilibrative nucleoside
8
transporters ents
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!